<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683995</url>
  </required_header>
  <id_info>
    <org_study_id>2246-0703</org_study_id>
    <nct_id>NCT00683995</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Study of KW-2246</brief_title>
  <official_title>A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as
      rescue medication for breakthrough pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pain, Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-2246 (fentanyl citrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-2246 (fentanyl citrate)</intervention_name>
    <description>KW-2246 (fentanyl citrate)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent to participate in the study on a voluntary basis.

          -  Patients who have been eligible for the confirmatory trial by meeting the inclusion
             criteria applicable at the time of giving written informed consent and those
             applicable at the time of randomization, and who have completed the confirmatory
             trial.

          -  Outpatients who live with a caregiver such as a family member, or inpatients.

          -  Require rescue medication at least 0.5 times (at least once every two days) but not
             more than three times per day on average as determined by the investigator.

          -  Performance Status (ECOG) of 3 or less at the time of giving written informed consent.

          -  Have a life expectancy of at least three months as determined by the investigator.

          -  Be able to receive diary training and have been able to properly complete diaries
             during the confirmatory trial.

        Exclusion Criteria:

          -  Have experienced intolerable adverse reactions (as defined in Attachment 3) during the
             confirmatory trial.

          -  Have met any of the exclusion criteria applicable at the time of giving written
             informed consent, those applicable at the time of randomization, or subject withdrawal
             criteria in the confirmatory trial.

          -  Serious respiratory dysfunction.

          -  Asthma.

          -  Serious bradyarrhythmia.

          -  Serious hepatic dysfunction.

          -  Serious renal dysfunction.

          -  Susceptibility to respiratory depression due to conditions such as increased
             intracranial pressure, head injury and brain tumor.

          -  Patients who have a history of clinically significant adverse reactions to the
             combination of opioid analgesics and any of the following drugs/substances, and who
             are currently receiving or expect to receive any of them during the study:

        Central nervous system depressants (phenothiazines, benzodiazepines and barbiturates),
        inhalation anesthetics, monoamine oxidase inhibitors, tricyclic antidepressants, skeletal
        muscle relaxants, antihistamines, ritonavir, alcohol, itraconazole, amiodarone,
        clarithromycin, diltiazem, and fluvoxamine.

          -  History of convulsive seizures (except a single episode of infantile febrile
             convulsions).

          -  History of hypersensitivity to fentanyl.

          -  Pregnant or lactating women, possibly pregnant women, or women who are planning to
             become pregnant.

          -  Patients who are judged by the investigator/subinvestigator to be inappropriate for
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Hakko Kirin Co., Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

